Recent Finacing
Recent Raise
Agomab develops organ‑restricted ALK5 inhibitors and HGF‑mimetic MET agonist antibodies to modulate fibrosis and promote tissue regeneration, advancing gut‑ and lung‑restricted small‑molecule and antibody programs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
